Abeona Therapeutics Q1 2024 GAAP EPS $(1.16) Misses $(0.51) Estimate
Portfolio Pulse from Benzinga Newsdesk
Abeona Therapeutics reported a Q1 2024 GAAP EPS of $(1.16), significantly missing the estimate of $(0.51).
May 15, 2024 | 11:40 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Abeona Therapeutics reported a Q1 2024 GAAP EPS of $(1.16), which is significantly below the estimated $(0.51). This substantial miss is likely to negatively impact the stock price in the short term.
The significant miss in earnings per share (EPS) compared to the estimate indicates potential financial struggles or unexpected expenses, which typically leads to a negative market reaction and a decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100